Table 1 Clinical details
From: Paclitaxel-induced neuropathy: potential association of MAPT and GSK3B genotypes
Clinical variables | |
|---|---|
Age (mean ± sem; years) | 51.4 ± 2.1 |
Range (years) | 33 – 68 |
% Female | 95.2% |
Cumulative paclitaxel dose (mg/m2) | 965.5 ± 80 |
Range (mg/m2) | 420 - 2230 |
Estrogen and/progesterone receptor positive | 80% |
HER-2/neu positive | 40% |
Cancer type – breast cancer | 95.2% |
Cancer stage | |
I - IIB | 47.6% |
IIIA - IIIB | 47.6% |
IV | 4.8% |